Cirrhosis of the Liver Clinical Trial
— LowMELDOfficial title:
Health-Related Quality of Life in the Low Model for End-Stage Liver Disease (MELD) Pre Transplant Patient Candidate: A Pilot Study
Verified date | February 2014 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study is to describe the HRQoL in those with MELD scores </= 15 in a single center for those who are pre-liver transplant candidates
Status | Completed |
Enrollment | 50 |
Est. completion date | July 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Must be a patient in the liver transplant clinic at Northwestern Memorial Hospital or one of its satellite clinics (including Washington, Illinois; Portage, Indiana; Glenview, Illinois, Oakbrook, Illinois; Joliet, Illinois) 2. Adult patient between the ages of 18-75 3. Ability to read and speak English 4. Must be a candidate for liver transplant per Northwestern Memorial Hospital liver transplant multidisciplinary committee 5. Model for End Stage Liver Disease (MELD) score =15 6. Cognitive ability to complete measures Exclusion Criteria: 1. Non-English speaking 2. Those who have already received a liver transplant 3. Hepatic encephalopathy as evidenced by: 1. Grade II or more West Haven Criteria or Adapted West Haven Criteria 2. Evidence of Asterixis upon exam at time of consent (if consented in person) 4. Acute liver failure as etiology for liver disease. 5. MELD score > 15 6. Mental retardation or cognitive disabilities preventing completion of the written questionnaire |
N/A
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Loyola University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perceived HRQoL Score. Overall Qualty of Life Index Tool Was Utilized. | Describe perceived HRQoL in patients with low MELD scores (=15) pre-liver transplant patient population. Overall Qualty of Life Index tool was utilized. The subscales were not utilized. The unit of measurement was scores on a scale. QLI tool has a range of 0-30 for total possible score. With the higher the score the higher the HRQoL. | 2-3 months | No |
Secondary | Percentage of Subjects With Depressive Scores Who Had a Poor HRQoL | Identify clinical characteristics such as environmental factors, patient biology, liver-disease related symptoms, functional status, general health perception, characteristics of the individual associated with perceived HRQoL in patients with low MELD scores (=15) pre-transplant. What characteristics were found to be predictive of poor HRQoL. Tools utilized each assessed the specific variables including patient biology, liver disease symptoms, functional status, general health perception, and characteristics of the individual. | 2-3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05178303 -
Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
|
N/A | |
Enrolling by invitation |
NCT06121492 -
Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
|
Phase 3 | |
Completed |
NCT04243148 -
Frailty in Patients With Cirrhosis: Prognostic Value of the Phase Angle in Hospitalized Patients and Effect of Multifactorial Intervention
|
N/A | |
Completed |
NCT02862249 -
Trial of Faecal Microbiota Transplantation in Cirrhosis
|
Phase 3 | |
Completed |
NCT02608658 -
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
|
N/A | |
Withdrawn |
NCT02809248 -
The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)
|
N/A | |
Recruiting |
NCT04116242 -
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease
|